Abstract 950P
Background
In this study, we aimed to evaluate the safety and efficacy of combining PD-1 antibody Tislelizumab with Sorafenib for the treatment of advanced hepatocellular carcinoma(HCC). Additionally, we sought to investigate the relationship between the circulating tumor cells (CTCs) count/ programmed death-ligand 1 (PD-L1) expression of CTCs and the prognosis of patients with advanced hepatocellular carcinoma.
Methods
The study Enrolled patients (pts) with unresectable HCC patients (pts) to receive tislelizumab combined with sorafenib. Tislelizumab, 200mg/q3w intravenous infusion, sorafenib 400 mg/bid oral dose; Evaluate every 3 cycles (9 weeks) to evaluate the safety and effectiveness of the drug regimen CTCs count and PD-L1 expression of CTCs were performed in all patients before enrollment. Primary endpoint was ORR by RECISTv1.1 per investigators. The secondary endpoints aimed to assess the relationship between the count of CTCs or the expression of PD-L1 and the prognosis of HCC.
Results
As of November 2022, 32 patients were enrolled in the study received combination treatment. For 32 pts, ORR was 17% (95% CI 33.0%-75.2%) and DCR was 65% (95% CI 71.2%-91.9%) by RECIST v1.1. When evaluated by mRECIST, ORR and DCR improved to 24.2% (95% CI 55.8%-93.8%) and 75% (95% CI 74.2%-92.9%), respectively. Treatment-emergent adverse events (TEAEs) occurred in 75% of pts, 35% of which was ≥grade 3. Of which 31 patients (96.8%) were positive for CTC, ranging from 1 to 45, with a median of 7 (3, 11), 25 (78.1%) PD-L1+CTC was detected in 32 patients. The median follow-up time was 6 months (range, 2-14 months). Correlation analysis found that The 1-year progression-free survival rates of patients in the PD-L1+CTC group and those in the non-detected PD-L1+CTC group were 54.1% vs 28.6% respectively (P=0.036).
Conclusions
Tislelizumab combination with Sorafenib showed promising antitumor activity with relatively high ORR and a tolerable safety profile in 1st line HCC treatment. Baseline CTC PD-L1+ can be used as a predictive indicator for screening HCC patients for PD-1/PD-L1 blockade therapy, and dynamic measurement of CTC changes can monitor the therapeutic effect of patients.
Clinical trial identification
ChiCTR2100050076.
Editorial acknowledgement
Legal entity responsible for the study
Che Xu.
Funding
Sanming Project of Medicine in Shenzhen (No.SZSM202011010) and Shenzhen High-level Hospital Construction Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18